Early access schemes for innovative health technologies: the views of international stakeholders
dc.contributor.author | Farmer, C | |
dc.contributor.author | O'Toole, B | |
dc.contributor.author | Barnish, MS | |
dc.contributor.author | Trigg, LA | |
dc.contributor.author | Hayward, S | |
dc.contributor.author | Crathorne, L | |
dc.contributor.author | Kasten, Z | |
dc.contributor.author | Spoors, J | |
dc.contributor.author | Melendez-Torres, GJ | |
dc.date.accessioned | 2023-11-06T15:14:18Z | |
dc.date.issued | 2023-07-06 | |
dc.date.updated | 2023-11-06T14:19:36Z | |
dc.description.abstract | OBJECTIVES: Early access schemes (EASs) are approaches used by payers to balance and facilitate earlier patient access to innovative health technologies while evidence generation is ongoing. Schemes require investment from payers and are associated with significant risk since not all technologies will be routinely reimbursed. The purpose of this study was to gain the perspectives of policy experts about the key challenges for EASs and potential solutions for their optimal design and implementation. METHODS: Two virtual workshops were convened including (i) UK-based policy experts (England, Wales, and Scotland) and (ii) representatives from multiple healthcare systems (England, France, Sweden, Canada, Poland, and Norway). Participants were encouraged to share their experiences with EASs in their healthcare system and highlight key challenges for policy makers. Discussions were transcribed and analyzed using framework analysis. RESULTS: Participants agreed that EASs have value when targeted toward innovative technologies with the potential for significant clinical benefit in an area of high unmet need. Participants discussed potential solutions to the challenges faced by payers implementing EASs, including defining eligibility criteria, supporting evidence generation, and approaches to reimbursement. CONCLUSIONS: Participants agreed that EASs are one possible solution for their healthcare systems and have the potential to deliver significant clinical value to patients. However, widespread adoption of EASs is limited due to concerns about the risks for patients and healthcare budgets, further solutions are needed to deliver EASs for targeted therapies. | en_GB |
dc.description.sponsorship | NHS England | en_GB |
dc.format.extent | e45- | |
dc.format.medium | Electronic | |
dc.identifier.citation | Vol. 39(1), article e45 | en_GB |
dc.identifier.doi | https://doi.org/10.1017/S0266462323000429 | |
dc.identifier.uri | http://hdl.handle.net/10871/134444 | |
dc.identifier | ORCID: 0000-0003-3553-8970 (Farmer, Caroline) | |
dc.identifier | ORCID: 0000-0002-9823-4790 (Melendez-Torres, GJ) | |
dc.identifier | ScopusID: 57188672699 (Melendez-Torres, GJ) | |
dc.language.iso | en | en_GB |
dc.publisher | Cambridge University Press (CUP) | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/37409515 | en_GB |
dc.rights | © The Author(s), 2023. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. | en_GB |
dc.subject | biomedical | en_GB |
dc.subject | health | en_GB |
dc.subject | health policy | en_GB |
dc.subject | insurance | en_GB |
dc.subject | investigational | en_GB |
dc.subject | reimbursement | en_GB |
dc.subject | technology assessment | en_GB |
dc.subject | therapies | en_GB |
dc.title | Early access schemes for innovative health technologies: the views of international stakeholders | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2023-11-06T15:14:18Z | |
dc.identifier.issn | 0266-4623 | |
exeter.article-number | e45 | |
exeter.place-of-publication | England | |
dc.description | This is the final version. Available on open access from Cambridge University Press via the DOI in this record | en_GB |
dc.identifier.eissn | 1471-6348 | |
dc.identifier.journal | International Journal of Technology Assessment in Health Care | en_GB |
dc.relation.ispartof | Int J Technol Assess Health Care, 39(1) | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2023-06-12 | |
dc.rights.license | CC BY | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2023-07-06 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2023-11-06T15:12:35Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2023-11-06T15:14:23Z | |
refterms.panel | A | en_GB |
refterms.dateFirstOnline | 2023-07-06 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © The Author(s), 2023. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.